Finally, we concluded that BRD4‐targeted therapy sensitized NSCLC to chemoradiation and anti‐PD‐1 antibody through a CD8+ T cell‐dependent mechanism without increasing the incidence and level of side effects. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.